Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
CJC-1295 with Ipamorelin
Add to protocol
Build with CJC-1295/Ipamorelin
Compare prices
Pharmacies & vendors
Calculate dosing
Reconstitution
A combination of CJC-1295 (a growth hormone releasing hormone analog) and Ipamorelin (a growth hormone secretagogue) that work synergistically to increase natural growth hormone production.
CJC-1295 acts on the GHRH receptor to stimulate GH release, while Ipamorelin acts on the ghrelin receptor. Together they produce a more robust GH pulse while maintaining normal pulsatile release patterns.
Both compounds are well-characterized individually. The combination is the most common GH-secretagogue pairing in peptide research protocols. The "no DAC" specification refers to CJC-1295 without Drug Affinity Complex, which has a shorter half-life but more physiological GH pulsatility.
Typical Dose
300mcg
Range
200-400mcg
Frequency
1x/day before bed (subcutaneous)
Route
SubQ
Duration
8-12 weeks
Reconstitution
5mg vial + 2.5mL bacteriostatic water = 2,000mcg/mL
Notes
Standard sizes: 10mg (5/5) and 20mg (10/10). "No DAC" is the standard research form. Lyophilized powder, reconstitute with bacteriostatic water. Store at 2-8°C.
These biomarkers are commonly tracked to assess response and safety. Run baseline labs before starting, mid-cycle labs halfway through, and post-cycle labs 1–2 weeks after the final dose.
Build a protocol with CJC-1295/Ipamorelin, schedule blood work for key biomarkers, and track your results.
Build Protocol with CJC-1295/IpamorelinThis platform provides informational tools only, not medical advice. This information is for educational purposes only. Consult a licensed provider.
Disclosed Labs